||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Evotec announces Research Agreement with Biogen Idec

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




- Evotec will use its expertise and capabilities in compound
screening to identify hit compounds

Hamburg, Germany / Oxford, UK - Evotec AG (Frankfurt Stock Exchange:
EVT; NASDAQ: EVTC), a leading provider in the discovery and
development of novel small molecule drugs, today announced that it
has entered into a research agreement with Biogen Idec (NASDAQ:
BIIB), a leading biopharmaceutical company headquartered in
Cambridge, Mass., USA.

Evotec will use its expertise and technologies in protein production,
assay development and high throughput screening to identify hit
molecules for Biogen Idec. Under the research agreement Evotec will
screen a target selected by Biogen Idec with the option to add
further targets as agreed. Evotec will provide Biogen Idec with
access to its full range of screening technologies and diverse
library of high quality compounds and will use its expertise in
protein production and assay development to develop new assays for
the target.

Dr Mark Ashton, Evotec's EVP, Business Development commented: "We
believe that the quality of future drug candidates is very much
dependant on the identification of high quality starting points. To
this end we have established a platform of screening technologies
that have been proven to identify high-class hit molecules. We are
looking forward to working with Biogen Idec and identifying
interesting hit compounds for them."

Evotec has built a comprehensive platform of hit finding technologies
that allow it to screen challenging targets and identify new classes
of hit compounds that can be progressed towards new treatments for
various diseases. These proven screening technologies coupled with
Evotec's high quality screening library have been shown to unlock
numerous biological targets and identify excellent start points for
subsequent optimization.

No financial details are disclosed.


For further information, please contact:
Dr Werner Lanthaler
Chief Executive Officer
Evotec AG
+49.(0)40.56081-242,
werner.lanthaler@evotec.com

Karen Slack
De Facto Communications
T : +44 (0) 20 7861 3043
E : k.slack@defacto.com

Forward-looking statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning
regulatory, clinical and business strategies, the progress of our
clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans,
objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond our control, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that the Company may
be unable to reduce its cash burn through recent restructuring and
cost containment measures and may not recognize the results of such
measures within the expected timeframe; risks that product candidates
may fail in the clinic or may not be successfully marketed or
manufactured; the risk that we will not achieve the anticipated
benefits of our collaborations, partnerships and acquisitions in the
timeframes expected, or at all; risks relating to our ability to
advance the development of product candidates currently in the
pipeline or in clinical trials; our inability to further identify,
develop and achieve commercial success for new products and
technologies; the risk that competing products may be more
successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial
success for our products and technologies; our inability to protect
our intellectual property and the cost of enforcing or defending our
intellectual property rights; our failure to comply with regulations
relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our
studies differently than we have; the risk that clinical trials may
not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug
candidates; and risks of new, changing and competitive technologies
and regulations in the U.S. and internationally.
The list of risks above is not exhaustive. Our most recent Annual
Report on Form 20-F, filed with the Securities and Exchange
Commission, and other documents filed with, or furnished to the
Securities and Exchange Commission, contain additional factors that
could impact our businesses and financial performance. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances
on which any such statement is based.



--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.072 Sekunden